Review
Open access
Published: 18 September 2026
Management of Immune Checkpoint Inhibitor-Related Toxicities: Multidisciplinary Consensus from Oncology Clinical Pharmacy Specialists
Sarah Jenkins, PharmD, BCOP; Ahmed Al-Mansoor, MD, PhD; Katherine B. Sterling, JD
Abstract
Multidisciplinary consensus recommendations for diagnosing, staging, and treating immunotherapy-mediated adverse events including colitis, pneumonitis, and endocrinopathies.
Abstract
Immune checkpoint inhibitors (ICIs) have revolutionized solid tumor therapeutics, yet immune-related adverse events (irAEs) present diagnostic and clinical management dilemmas across organ systems. This clinical consensus provides standardized grading, immunosuppressive protocols, and monitoring guidelines for clinical pharmacy practitioners.
- DOI
- 10.1007/s11096-026-01832-1
- Volume / Issue
-
Volume 1, Issue 3 — Pages 125-142
- Published
- 18 September 2026
- Journal
- International Journal of Clinical Pharmacy and Medicine (IJCPM)